Pulmo BioTech

Pulmo BioTech is a development-stage biotechnology company specializing in innovative molecular imaging diagnostics for pulmonary diseases. Its lead product candidate, PulmoBind (DFH-12), is a radiolabeled peptide designed to bind specifically to adrenomedullin receptors in the lung's vascular endothelium. This technology enables non-invasive, 3D visualization of the pulmonary circulatory system using standard gamma cameras, offering a potential replacement for traditional diagnostic methods for pulmonary embolism and pulmonary arterial hypertension. The company operates primarily through its subsidiary, PulmoScience, and maintains a long-standing partnership with the Montreal Heart Institute, where the technology originated. PulmoBind has successfully completed Phase 2 clinical trials, demonstrating its ability to detect vascular defects in patients with pulmonary hypertension.